Used in pharmaceutical research as a potent and selective antagonist for dopamine D4 receptors, this compound is investigated for its potential in treating central nervous system disorders such as schizophrenia, attention deficit hyperactivity disorder (ADHD), and substance abuse. Its structure allows for high blood-brain barrier penetration and receptor specificity, making it a valuable scaffold in the development of novel neuropsychiatric medications. It has also been employed as a radiolabeled ligand in positron emission tomography (PET) studies to map D4 receptor distribution in the brain.